Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.727
Index Copernicus  – 166.39
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2015, vol. 24, nr 1, January-February, p. 85–92

doi: 10.17219/acem/38141

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Adiponectin Levels in Gestational Diabetes Mellitus and in Pregnant Women Without Glucose Intolerance

Halil G. Pala1,A,B,C,D, Yılmaz Ozalp2,A,B, Abdullah S. Yener3,C,D, Gul Gerceklioglu4,B,C, Sezer Uysal5,E,F, Ata Onvural6,E,F

1 Department of Obstetrics and Gynecology, Perinatology Division, Celal Bayar University, School of Medicine, Manisa, Turkey

2 Elbistan Government Hospital, Kahramanmaras, Turkey

3 Department of Internal Medicine, Division of Endocrinology, Dokuz Eylul University, School of Medicine, Izmir, Turkey

4 Celal Bayar University, Vocational School of Health Sciences, Manisa, Turkey

5 Biochemistry Department, Dokuz Eylul University, School of Medicine, Izmir, Turkey

6 Obstetrics and Gynecology Department, Dokuz Eylul University, School of Medicine, Izmir, Turkey

Abstract

Objectives. The aim of the study was to determine serum adiponectin levels among patients with gestational diabetes mellitus (GDM) and normal pregnant women without glucose intolerance, and to investigate the relationship between these levels and clinical factors at the time of the diagnosis, at delivery and in the post-partum period.
Material and Methods. The subjects’ serum adiponectin concentration was measured using the enzyme-linked immunosorbent assay (ELISA) method at 24th–28th week of gestation, at delivery (in maternal circulation and the umbilical cord) and 24 h after delivery. The relationship between these groups’ measurements and other established clinical-laboratory factors were investigated.
Results. Serum adiponectin concentrations were significantly lower (p = 0.02) in GDM patients compared with patients with normal glucose tolerance at 24th–28th week of gestation. During delivery, maternal serum adiponectin concentrations were significantly lower (p = 0.03) in GDM patients compared with patients with normal glucose tolerance. In the post-partum period, serum adiponectin concentrations were significantly higher (p = 0.009) in GDM patients compared with patients with normal glucose tolerance. Umbilical cord adiponectin concentrations were significantly lower (p = 0.005) in GDM patients compared with patients with normal glucose tolerance.
Conclusion. Adiponectin concentrations in GDM patients’ circulation were regulated by changes in glucose and insulin metabolism. A reduction in serum adiponectin levels seems to play a role in GDM patients’ insulin resistance.

Key words

gestational diabetes mellitus, adiponectin, insulin resistance, glucose intolerance, adipokines.

References (28)

  1. Buchanan TA, Xiang AH: Gestational diabetes mellitus. J Clin Invest 2005, 115, 485–491.
  2. Yamashita H, Shao J, Friedman JE: Physiologic and molecular alterations in carbohydrate metabolism during pregnancy and gestational diabetes mellitus. Clin Obstet Gynecol 2000, 43, 87–98.
  3. Xiang AH, Peters RK, Trigo E, Kjos SL, Lee WP, Buchanan TA: Multiple metabolic defects during late pregnancy in women at high risk for type 2 diabetes. Diabetes 1999, 48, 848–854.
  4. Position Statement. Gestational Diabetes mellitus. Diabet Care 2004, 27, 88–90.
  5. Ategbo JM, Grissa O, Yessoufou A, Hichami A, Dramane KL, Moutairou K: Modulation of adipokines and cytokines in gestational diabetes and macrosomia. J Clin Endocrinol Metab 2006, 91, 4137–4143.
  6. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257, 79–83.
  7. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J: Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002, 277, 25863–25866.
  8. Carpenter MW: Gestational diabetes, pregnancy hypertension, and late vascular disease. Diabetes Care 2007, 30, 246–250.
  9. Metzger BE: Summary and Recommendations of Fourth Internal WorkshopConference on Gestational Diabetes. Diabetes Care 1998, 21, 161–167.
  10. Kinalski M, Telejko B, Kuzmicki M, Kretowski A, Kinalska I: Tumor necrosis factor a system and plasma adiponectin concentration in women with gestational diabetes. Horm Metab Res 2005, 37, 450–454.
  11. McLachlan KA, O’Neal D, Jenkins A, Alford FP: Do adiponectin, TNFa, leptin and CRP relate to insulin resistance in pregnancy? Studies in women with and without gestational diabetes, during and after pregnancy. Diabetes Metab Res Rev 2005, 22, 131–138.
  12. Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K: Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein cholesterol, independent of body mass index, in the Japanese population. Clin Sci 2002, 103, 137–142.
  13. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S: Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003, 52, 239–243.
  14. Wilson JD, Poster DW: Diabetes in Williams Textbook of Endocrinology. WB Saunders Company 1992, 8th ed, 993–1005.
  15. Hollingsworth AK: Endocrin and metabolic homeostasis in diabetic pregnancy. Clin Perinatol 1983, 10, 593–598.
  16. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y: Plasma concentration of a novel adipose specific protein adiponectin in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20, 1595–1599.
  17. Sagawa N, Yura S, Itoh H, Kakui K, Takemura M, Nuamah MA: Possible role of placental leptin in pregnancy: a review. Endocrine 2002, 19, 65–71.
  18. Altınova AE, Toruner F, Bozkurt N, Bukan N, Karakoç A, Yetkin I: Circulating concentrations of adiponectin and tumor necrosis factor-α in gestational diabetes mellitus. Gynecol Endocrinol 2007, 23, 161–165.
  19. Cseh K, Baranyi E, Melczer Z, Kaszas E, Palik E, Winkler G: Plasma adiponectin and pregnancy-induced insulin resistance. Diabetes Care 2004, 27, 274–275.
  20. Ramos MP, Crespo-Solans MD, del Campo S, Cacho J, Herrera F: Fat accumulation in the rat during early pregnancy is modulated by enhanced insulin responsiveness, Am J Physiol Endocrinol Metab 2003, 285, 318–328.
  21. Lo´pez-Luna P, Maier I, Herrera E: Carcass and tissue fat content in the pregnant rat. Biol Neonate 1991, 60, 29–38.
  22. Lappas M, Yee K, Permezel M, Rice GE: Release and regulation of leptin, resistin and adiponectin from human plasenta, fetal membranes, and maternal adipose tissue and skeletal muscle from normal and gestational diabetes mellitus-complicated pregnancies. J Endocrinol 2005, 186, 457–465.
  23. Corbetta S, Bulfamante G, Cortelazzi D, Barresi V, Cetin I, Mantovani G: Adiponectin expression in human fetal tissues during midand late gestation. J Clin Endocrinol Metab 2005, 90, 2397–2402.
  24. Kajantie E, Hytinantti T, Hovi P, Andersson S: Cord plasma adiponectin: a 20-fold rise between 24 weeks gestation and term. J Clin Endocrinol Metab 2004, 89, 4031–4036.
  25. Weyermann M, Beermann C, Brenner H, Rothenbacher D: Adiponectin and leptin in maternal serum, cord blood, and breast milk. Clin Chem 2006, 52, 2095–2102.
  26. Chan TF, Yuan SS, Chen HS, Guu CF, Wu LC, Yeh YT: Correlations between umbilical and maternal serum adiponectin levels and neonatal birthweights. Acta Obstet Gynecol Scand 2004, 83, 165–169.
  27. Sivan E, Mazaki-Tovi S, Pariente C, Efraty Y, Schiff E, Hemi R: Adiponectin in human cord blood: relation to fetal birth weight and gender. J Clin Endocrinol Metab 2003, 88, 5656–5660.
  28. Abbasi F, Chu JW, Lamendola C, McLaughlin T, Hayden J, Reaven GM: Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes 2004, 53, 585–590.